CK Biotech. is a biotech-based company founded in October, 2016 aiming to develop First-in-Class drugs addressing unmet medical needs. The company was established on the basis of the Transnational Research Center for Protein Function Control (TRCP/ ERC), a government-supported drug development institute, which has been directed by the CEO of CK Biotech., Dr. Kang-Yell Choi, for more than 10 years.
The excellence of R&D achievements of his research team was proven by several times selections of the nationally honorary awards such as “National R&D Excellence of 100” and “excellent basic research award”. He also successfully performed the major national projects for drug development such as “Korea Drug Development Fund” and “National OcoVentrue Fund”.
Currently, on the basis of the previous outcomes form TRCP, we are specially interested in the drugs targeting the signaling pathways involved in tissue regeneration. By controlling the specific disease marker, which is overexpressed in the several target diseases, we are developing drugs selectively function to the patients, but not to healthy persons. The drugs under development by CK Biotech Inc. include the orally applicable drugs targeting obesity, diabetes, and non-alcoholic steatohepatitis (NASH), as well as the topically applicable drugs promoting hair growth and wound healing.
We will be appreciate for your encouragement to the future of CK Biotech Inc. aiming to stand as a leader in the future bio-medical industry.